CLYM (Climb Bio) Quality Rank


CLYM Climb Bio Inc CLYM
22 GF Score
Price $13.81
! 3 Warning Signs
View Full Analysis

What is Climb Bio Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Climb Bio Quality Rank Related Terms

CLYM
22GF Score
Climb Bio Inc CLYM
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.81
Price